Marvell Technology Group, Ltd. Securities Litigation

On October 27, 2017 the Honorable William Alsup of the United States District Court for the Northern District of California certified a class of investors who purchased or otherwise acquired Marvell Techonology Group, Ltd. common stock from February 19, 2015 through December 7, 2015. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided an expert report about market efficiency. Additional information is available here.

Silver Wheaton Corp. Securities Litigation

On May 13, 2017 the Honorable Christina A. Synder of the United States District Court for the Central District of California certified a class of investors who purchased or otherwise acquired Silver Wheaton Corp. common stock from March 30, 2011 through July 6, 2015. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided an expert report about market efficiency. In particular, the Court noted "Damages for every class member can be mechanically calculated according to Feinstein’s proposed methodology and are ...

STAAR Surgical Company Securities Litigation

On January 5, 2017 the Honorable Michael W. Fitzgerald of the United States District Court for the Central District of California certified a class of investors who purchased or otherwise acquired STAAR Surgical Company common stock between November 1, 2013 and June 30, 2014. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided an expert report about market efficiency. Additional information is available here.

Urban Outfitters, Inc. Securities Litigation

On June 8, 2016, parties in the Urban Outfitters, Inc. securities litigation reached an agreement to settle the case.  Plaintiffs alleged that Urban Outfitters, Inc. made misstatements regarding its sales trends. Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided expert reports about market efficiency. Additional information is available here.

Intercept Pharmaceuticals Inc. Securities Litigation

On 6 May 2016, parties in the Intercept Pharmaceuticals Inc. securities litigation reached an agreement to settle the case.  Plaintiffs alleged that Intercept made misstatements and omissions in connection with the negative effects of its lead drug, obeticholic acid.  Professor Steven Feinstein of Babson College and Crowninshield Financial Research provided expert reports and deposition testimony about market efficiency. Additional information is available here.